Business Description
Cellectis SA
ISIN : FR0010425595
Compare
Compare
Traded in other countries / regions
ALCLS.FranceCLLS.USA0WA2.UKZVA.Germany IPO Date
2007-02-19Description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.4 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 1 | |||||
| Debt-to-EBITDA | -0.96 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.8 | |||||
| Beneish M-Score | 44.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -77 | |||||
| 3-Year EBITDA Growth Rate | -21.1 | |||||
| 3-Year EPS without NRI Growth Rate | -44.9 | |||||
| 3-Year FCF Growth Rate | 44.4 | |||||
| 3-Year Book Growth Rate | -41.7 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.63 | |||||
| 9-Day RSI | 51.56 | |||||
| 14-Day RSI | 53.44 | |||||
| 6-1 Month Momentum % | -4.96 | |||||
| 12-1 Month Momentum % | 46.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.5 | |||||
| Quick Ratio | 1.5 | |||||
| Cash Ratio | 1.31 | |||||
| Days Sales Outstanding | 318.59 | |||||
| Days Payable | 10165.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.8 | |||||
| Shareholder Yield % | -20.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 2 | |||||
| Operating Margin % | -12887.71 | |||||
| Net Margin % | -13371.71 | |||||
| FCF Margin % | -3517.86 | |||||
| ROE % | -102.7 | |||||
| ROA % | -39.18 | |||||
| ROIC % | -62.43 | |||||
| ROC (Joel Greenblatt) % | -105.56 | |||||
| ROCE % | -57.68 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 200 | |||||
| PB Ratio | 2.4 | |||||
| Price-to-Tangible-Book | 2.42 | |||||
| EV-to-EBIT | -1.52 | |||||
| EV-to-EBITDA | -1.84 | |||||
| EV-to-Revenue | 214.53 | |||||
| EV-to-Forward-Revenue | 22.86 | |||||
| EV-to-FCF | -6.1 | |||||
| Earnings Yield (Greenblatt) % | -65.79 | |||||
| FCF Yield % | -9.48 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cellectis SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.7 | ||
| EPS (TTM) (€) | -1.649 | ||
| Beta | 3.72 | ||
| Volatility % | 223.64 | ||
| 14-Day RSI | 53.44 | ||
| 14-Day ATR (€) | 0.061654 | ||
| 20-Day SMA (€) | 2.64675 | ||
| 12-1 Month Momentum % | 46.57 | ||
| 52-Week Range (€) | 0.8765 - 3.194 | ||
| Shares Outstanding (Mil) | 99.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cellectis SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cellectis SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cellectis SA Frequently Asked Questions
What is Cellectis SA(FRA:ZVA)'s stock price today?
The current price of FRA:ZVA is €2.67. The 52 week high of FRA:ZVA is €3.19 and 52 week low is €0.88.
When is next earnings date of Cellectis SA(FRA:ZVA)?
The next earnings date of Cellectis SA(FRA:ZVA) is 2024-08-02 Est..
Does Cellectis SA(FRA:ZVA) pay dividends? If so, how much?
Cellectis SA(FRA:ZVA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers